Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How would you manage a patient with esophageal SCC that completed concurrent chemoradiation without definitive surgery with imaging evidence of local progression but biopsies only show focal dysplasia?
Related Questions
Would you recommend additional post-operative chemoradiation for a T2N1 proximal rectal cancer having received adjuvant capecitabine/oxaliplatin?
In which situations do you omit the 5FU bolus in FOLFOX or FOLFIRI?
What is your second line therapy for PDL1 negative metastatic squamous esophageal cancer who did not receive a checkpoint inhibitor in first line setting?
How would you treat a synchronous low rectal adenocarcinoma and anal squamous cell carcinoma with involved pelvic and inguinal nodes?
Which adjuvant chemotherapy would you offer to a MSI high pancreatic cancer patient after Whipple?
What is your preferred first line therapy for metastatic cholangiocarcinoma, if the patient is cisplatin ineligible or cisplatin is unavailable?
Would you offer adjuvant chemotherapy or radiation to a resected MSS T3N0 high-rectal lesion with low anterior resection without pre-op therapy?
Is there a role for further HER2 directed therapies after progression on fam-trastuzumab deruxtecan after a sustained initial response in patients with metastatic HER2+ colorectal cancer?
How do you dose FOLFOX when given with concurrent chemoradiation in esophageal adenocarcinoma?
What is your preferred neoadjuvant chemotherapy regimen for borderline resectable pancreatic ductal adenocarcinoma?